EU approval for Hetlioz (tasimelteon) to treat non-24-hour sleep-wake disorder- Vanda Pharma
Vanda Pharmaceuticals Inc.has announced that the European Commission (EC) approved Hetlioz (tasimelteon) for the treatment of non-24-hour sleep-wake disorder (Non-24) in totally blind adults in the European Union (EU).
Non-24 is a chronic circadian rhythm disorder resulting from the misalignment of the endogenous master body clock to the 24-hour day, disrupting the sleep-wake cycle. The sleep disturbance causes significant distress and/or impairment in social, occupational and other important areas of functioning. Non-24 affects the majority of totally blind individuals and it has been estimated that approximately 130,000 people in the European Union have the disorder.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins